⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
globenewswire.com
AIM
Pancreatic Cancer Diagnostics Research Report 2026
globenewswire.com
NVDA
AIM
ILMN
GH
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
globenewswire.com
AIM
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
globenewswire.com
AIM
AZN
AIM ImmunoTech Provides Routine Update on Annual Filings
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
globenewswire.com
AIM
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
globenewswire.com
ARTL
AIM
YYGH
AIMイムノテック、アンプリジェンとチェックポイント阻害剤を併用する新規がん治療法の、日本における特許の最終承認を発表
globenewswire.com
AIM
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
globenewswire.com
AIM